These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25921372)

  • 21. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is keeping the colon the ultimate marker of success in ulcerative colitis?
    Nguyen GC; Prather CM
    Gastroenterology; 2009 Oct; 137(4):1204-6. PubMed ID: 19717125
    [No Abstract]   [Full Text] [Related]  

  • 23. Combination therapy with infliximab and immunomodulators: is the glass half empty?
    Deshpande AR; Abreu MT
    Gastroenterology; 2008 Jun; 134(7):2161-3. PubMed ID: 18482585
    [No Abstract]   [Full Text] [Related]  

  • 24. Timing infliximab therapy in pediatric Crohn's disease.
    Kirschner BS; Huo D
    Gastroenterology; 2007 Mar; 132(3):1167-70. PubMed ID: 17383435
    [No Abstract]   [Full Text] [Related]  

  • 25. [Infliksimab in therapy of inflammatory bowels diseases].
    Kniazev OV; Lazebnik LB; Ruchkina IN; Tsaregorodtseva TN; Parfenov AI
    Eksp Klin Gastroenterol; 2009; (5):64-8. PubMed ID: 20201307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize.
    Sandborn WJ
    Gastroenterology; 2003 Apr; 124(4):1140-5. PubMed ID: 12671907
    [No Abstract]   [Full Text] [Related]  

  • 27. Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease.
    Bodini G; Giannini EG; Savarino V; Del Nero L; Lo Pumo S; Brunacci M; De Bortoli N; Jain A; Tolone S; Savarino E
    Dig Liver Dis; 2018 May; 50(5):452-456. PubMed ID: 29274766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current medical treatment of inflammatory bowel disease].
    Bosques-Padilla F
    Rev Gastroenterol Mex; 2007 Nov; 72 Suppl 2():92-101. PubMed ID: 18277494
    [No Abstract]   [Full Text] [Related]  

  • 29. [Therapy of chronic inflammatory bowel diseases].
    Stange EF
    Praxis (Bern 1994); 2002 Nov; 91(47):2029-39. PubMed ID: 12501498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Management of severe attack of ulcerative colitis].
    Tysk C; Almer S; Andersson MV; Befrits R; Hertervig E; Kilander A; Lindgren S; Suhr O
    Lakartidningen; 2009 Nov 4-12; 106(45):2994-8. PubMed ID: 19998825
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapeutic drug monitoring in inflammatory bowel disease.
    Jossen J; Dubinsky M
    Curr Opin Pediatr; 2016 Oct; 28(5):620-5. PubMed ID: 27583410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etrolizumab: anti-β7-a novel therapy for ulcerative colitis.
    Lin KK; Mahadevan U
    Gastroenterology; 2014 Jan; 146(1):307-9. PubMed ID: 24269566
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
    Chaparro M; Panes J; García V; Mañosa M; Esteve M; Merino O; Andreu M; Gutierrez A; Gomollón F; Cabriada JL; Montoro MA; Mendoza JL; Nos P; Gisbert JP
    J Clin Gastroenterol; 2011 Feb; 45(2):113-8. PubMed ID: 21242747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease.
    Chaparro M; Gisbert JP
    Aliment Pharmacol Ther; 2014 Jul; 40(1):120-1. PubMed ID: 24903436
    [No Abstract]   [Full Text] [Related]  

  • 35. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Better to start from top?].
    MMW Fortschr Med; 2005 Oct; 147(42):8. PubMed ID: 16281774
    [No Abstract]   [Full Text] [Related]  

  • 37. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
    Sandborn WJ; Rutgeerts P; Feagan BG; Reinisch W; Olson A; Johanns J; Lu J; Horgan K; Rachmilewitz D; Hanauer SB; Lichtenstein GR; de Villiers WJ; Present D; Sands BE; Colombel JF
    Gastroenterology; 2009 Oct; 137(4):1250-60; quiz 1520. PubMed ID: 19596014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Surgery, inflammatory bowel disease and biological treatment].
    Øresland T; Moum B
    Tidsskr Nor Laegeforen; 2009 Nov; 129(22):2389-90. PubMed ID: 19935950
    [No Abstract]   [Full Text] [Related]  

  • 40. Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease--authors' reply.
    Levesque BG; Feagan BG
    Aliment Pharmacol Ther; 2014 Jul; 40(1):121-2. PubMed ID: 24903437
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.